January 2026 — Houston / Amsterdam A first-of-its-kind vaccine designed to prevent fatal fentanyl overdoses is preparing to enter its initial human clinical trials, marking a potential breakthrough i...
Washington, Dec. 24, 2025 — The U.S. Food and Drug Administration has approved Yartemlea, a monoclonal antibody developed by Omeros Corporation, as the first treatment for transplant-associated throm...
The United Arab Emirates has become the second country in the world to approve the gene therapy Itvisma for the treatment of spinal muscular atrophy (SMA), marking another milestone in the global adop...
Paris / Seoul — Dec. 15, 2025 — French pharmaceutical company Sanofi has entered into a strategic collaboration with South Korean biotech firm ADEL worth up to USD 1.04 billion to jointly develop an...
Durham, NC — Dec. 12, 2025 — The U.S. Food and Drug Administration (FDA) has approved an oral pellet formulation of Orladeyo (berotralstat) from BioCryst Pharmaceuticals for prophylactic use in chil...
Washington, Dec. 9, 2025 — The U.S. Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), a gene therapy developed by nonprofit organization Fondazione Telethon ETS, for...
Boston, December 6, 2025Vertex Pharmaceuticals announced new clinical data demonstrating that its gene-editing therapy Casgevy (exagamglogene autotemcel, exa-cel) produced robust therapeutic benefits ...
December 3, 2025 — Capricor Therapeutics announced that its investigational cell therapy Deramiocel achieved both primary and key secondary endpoints in the pivotal Phase 3 HOPE-3 trial for Duchenne ...
December 1, 2025 — Regeneron Pharmaceuticals announced today a global collaboration with Tessera Therapeutics to develop and commercialize Tessera’s investigational in-vivo gene editing therapy TSRA...
South San Francisco, CA — November 3, 2025 — Biotech leader Genentech announced that it will present 46 abstracts, including 12 oral presentations, from its hematology portfolio at the upcoming ASH ...
A newly released market report on November 26, 2025 indicates that the global oncolytic virus CDMO services market is entering a phase of accelerated growth. According to the report, the market is pro...
Washington, Nov 24, 2025 — The U.S. Food and Drug Administration (FDA) has approved Itvisma, a gene therapy developed by Novartis, for a broader group of patients with spinal muscular atrophy (SMA), ...
86 198 5711 6962 
info@hillgene.com 
English
